Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06099366

Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in Children

Lymphoblastic Leukemia in Children Clinical Trial

Official title:
Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in

Clinical Trial Summary

Aim of this study is to investigate the outcome of NGS MRD based risk stratified treatment for standard risk acute lymphoblastic leukemia in children and adolescents.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06099366
Study type Interventional
Source Samsung Medical Center
Contact Hee Young Ju, MD, Phd
Phone 82-2-3410-0865
Email heeyoung.ju@samsung.com
Status Recruiting
Phase Phase 2
Start date March 5, 2024
Completion date December 31, 2033
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05043571 - CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia Phase 1
Completed NCT03595969 - Association Between Mitochondrial DNA Content and Risk of Acute Leukemia
Recruiting NCT05648019 - CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol Phase 2
Recruiting NCT05429905 - Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia Phase 1/Phase 2
Recruiting NCT05038696 - ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia. Phase 1